The Israel Diabetes and Cognitive Decline (IDCD) Study: Design and Baseline Characteristics

Overview

Journal Alzheimers Dement

Specialties Neurology
Psychiatry

Date 2014 Aug 25

PMID 25150735

Citations 33

Authors

Michal Schnaider Beeri

Ramit Ravona-Springer

Erin Moshier

James Schmeidler

James Godbold

Tomas Karpati

Derek LeRoith

Keren Koifman

Efrat Kravitz

Rachel Price

Hadas Hoffman

Jeremy M Silverman

Anthony Heymann

Affiliations

Soon will be listed here.

Abstract

Background: Type 2 diabetes (T2D) is associated with increased risk of dementia. The prospective longitudinal Israel Diabetes and Cognitive Decline study aims at identifying T2D-related characteristics associated with cognitive decline.

Methods: Subjects are population-based T2D 65+, initially cognitively intact. Medical conditions, blood examinations, and medication use data are since 1998; cognitive, functional, demographic, psychiatric, DNA, and inflammatory marker study assessments were conducted every 18 months. Because the duration of T2D reflects its chronicity and implications, we compared short (0-4.99 years), moderate (5-9.99), and long (10+) duration for the first 897 subjects.

Results: The long duration group used more T2D medications, had higher glucose, lower glomerular filtration rate, slower walking speed, and poorer cognitive functioning. Duration was not associated with most medical, blood, urine, and vital characteristics.

Conclusions: Tracking cognition, with face-to-face evaluations, exploiting 15 years of historical detailed computerized, easily accessible, and validated T2D-related characteristics may provide novel insights into T2D-related dementia.

Citing Articles

Amyloid deposition and small vessel disease are associated with cognitive function in older adults with type 2 diabetes.

Lesman-Segev O, Golan Shekhtman S, Springer R, Livny A, Lin H, Yuxia O Sci Rep. 2024; 14(1):2741.

PMID: 38302529 PMC: 10834442. DOI: 10.1038/s41598-024-53043-x.

Exendin-4 ameliorates tau hyperphosphorylation and cognitive impairment in type 2 diabetes through acting on Wnt/β-catenin/NeuroD1 pathway.

Kang X, Wang D, Zhang L, Huang T, Liu S, Feng X Mol Med. 2023; 29(1):118.

PMID: 37667187 PMC: 10478475. DOI: 10.1186/s10020-023-00718-2.

Decrease in Gait Speed Over Time Is Associated With Increase in Number of Depression Symptoms in Older Adults With Type 2 Diabetes.

Lavie I, Beeri M, Schwartz Y, Soleimani L, Heymann A, Azuri J J Gerontol A Biol Sci Med Sci. 2023; 78(8):1504-1512.

PMID: 36626301 PMC: 10395563. DOI: 10.1093/gerona/glad008.

Alzheimer's Disease Polygenic Risk Score Is Not Associated With Cognitive Decline Among Older Adults With Type 2 Diabetes.

Manzali S, Yu E, Ravona-Springer R, Livny A, Golan S, Ouyang Y Front Aging Neurosci. 2022; 14:853695.

PMID: 36110429 PMC: 9468264. DOI: 10.3389/fnagi.2022.853695.

Brain structural alterations detected by an automatic quantified tool as an indicator for MCI diagnosing in type 2 diabetes mellitus patients: A magnetic resonance imaging study.

Gu J, Cui S, Qi H, Li J, Wu W, Wang S Heliyon. 2022; 8(5):e09390.

PMID: 35647347 PMC: 9136264. DOI: 10.1016/j.heliyon.2022.e09390.

References

Strachan M, Deary I, EWING F, Frier B . Is type II diabetes associated with an increased risk of cognitive dysfunction? A critical review of published studies. Diabetes Care. 1997; 20(3):438-45. DOI: 10.2337/diacare.20.3.438. View

Schnaider Beeri M, Goldbourt U, Silverman J, Noy S, Schmeidler J, Ravona-Springer R . Diabetes mellitus in midlife and the risk of dementia three decades later. Neurology. 2004; 63(10):1902-7. DOI: 10.1212/01.wnl.0000144278.79488.dd. View

Allen K, Frier B, Strachan M . The relationship between type 2 diabetes and cognitive dysfunction: longitudinal studies and their methodological limitations. Eur J Pharmacol. 2004; 490(1-3):169-75. DOI: 10.1016/j.ejphar.2004.02.054. View

Craft S, Asthana S, Cook D, Baker L, Cherrier M, Purganan K . Insulin dose-response effects on memory and plasma amyloid precursor protein in Alzheimer's disease: interactions with apolipoprotein E genotype. Psychoneuroendocrinology. 2003; 28(6):809-22. DOI: 10.1016/s0306-4530(02)00087-2. View

Janson J, Laedtke T, Parisi J, OBrien P, Petersen R, Butler P . Increased risk of type 2 diabetes in Alzheimer disease. Diabetes. 2004; 53(2):474-81. DOI: 10.2337/diabetes.53.2.474. View

Marin D, Flynn S, Mare M, Lantz M, Hsu M, Laurans M . Reliability and validity of a chronic care facility adaptation of the Clinical Dementia Rating scale. Int J Geriatr Psychiatry. 2001; 16(8):745-50. DOI: 10.1002/gps.385. View

Schulz L, Bennett P, Ravussin E, Kidd J, Kidd K, Esparza J . Effects of traditional and western environments on prevalence of type 2 diabetes in Pima Indians in Mexico and the U.S. Diabetes Care. 2006; 29(8):1866-71. DOI: 10.2337/dc06-0138. View

Roman G, Tatemichi T, Erkinjuntti T, Cummings J, Masdeu J, Garcia J . Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology. 1993; 43(2):250-60. DOI: 10.1212/wnl.43.2.250. View

Twisk J, Rijmen F . Longitudinal tobit regression: a new approach to analyze outcome variables with floor or ceiling effects. J Clin Epidemiol. 2009; 62(9):953-8. DOI: 10.1016/j.jclinepi.2008.10.003. View

10.

Klein B, Klein R, Moss S . Self-rated health and diabetes of long duration. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. Diabetes Care. 1998; 21(2):236-40. DOI: 10.2337/diacare.21.2.236. View

11.

Yesavage J . Geriatric Depression Scale. Psychopharmacol Bull. 1988; 24(4):709-11. View

12.

Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L, Wahlund L . Mild cognitive impairment--beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med. 2004; 256(3):240-6. DOI: 10.1111/j.1365-2796.2004.01380.x. View

13.

Luchsinger J, Reitz C, Patel B, Tang M, Manly J, Mayeux R . Relation of diabetes to mild cognitive impairment. Arch Neurol. 2007; 64(4):570-5. DOI: 10.1001/archneur.64.4.570. View

14.

Gerstein H, Miller M, Genuth S, Ismail-Beigi F, Buse J, Goff Jr D . Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med. 2011; 364(9):818-28. PMC: 4083508. DOI: 10.1056/NEJMoa1006524. View

15.

Folstein M, Folstein S, McHugh P . "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975; 12(3):189-98. DOI: 10.1016/0022-3956(75)90026-6. View

16.

Aung P, Strachan M, Frier B, Butcher I, Deary I, Price J . Severe hypoglycaemia and late-life cognitive ability in older people with Type 2 diabetes: the Edinburgh Type 2 Diabetes Study. Diabet Med. 2011; 29(3):328-36. DOI: 10.1111/j.1464-5491.2011.03505.x. View

17.

Bruins P, Te Velthuis H, Yazdanbakhsh A, Jansen P, van Hardevelt F, de Beaumont E . Activation of the complement system during and after cardiopulmonary bypass surgery: postsurgery activation involves C-reactive protein and is associated with postoperative arrhythmia. Circulation. 1997; 96(10):3542-8. DOI: 10.1161/01.cir.96.10.3542. View

18.

Carey V, Walters E, Colditz G, Solomon C, Willett W, Rosner B . Body fat distribution and risk of non-insulin-dependent diabetes mellitus in women. The Nurses' Health Study. Am J Epidemiol. 1997; 145(7):614-9. DOI: 10.1093/oxfordjournals.aje.a009158. View

19.

Shalev V, Chodick G, Goren I, Silber H, Kokia E, Heymann A . The use of an automated patient registry to manage and monitor cardiovascular conditions and related outcomes in a large health organization. Int J Cardiol. 2010; 152(3):345-9. DOI: 10.1016/j.ijcard.2010.08.002. View

20.

Yaffe K, Kanaya A, Lindquist K, Simonsick E, Harris T, Shorr R . The metabolic syndrome, inflammation, and risk of cognitive decline. JAMA. 2004; 292(18):2237-42. DOI: 10.1001/jama.292.18.2237. View